Omnix Medical, a Jerusalem biotech working on anti-infective drugs, closed a $25 mn Series C funding round co-led by Harel Insurance & Finance and the European Innovation Council (EIC) Fund. Existing investors also renewed their backing.
Launched in 2015, the company develops engineered antimicrobial peptides aimed at severe bacterial infections. The new capital will bankroll Phase II proof-of-concept studies of its lead compound OMN6.
This latest raise follows an $8.5 mn round in November 2020, led by Tal Capital and Entrée Capital, alongside CBG Group, Xenia Ventures, VLX Ventures, and the Israeli Innovation Authority. Beyond these two disclosed events, the company’s overall funding picture looks inconsistent across sources.
Startup raised $46 mn in total across five rounds and seven investors. The most reliable milestones are the $8.5 mn in 2020 and the $25 mn Series C in 2025. Everything else depends on how you count.
Omnix received an EU Horizon 2020 award (Grant Agreement No 966627), and such non-dilutive capital often gets counted differently depending on the database. Smaller early rounds or angel checks may also have slipped under public disclosure.
What’s clear: Omnix sits at the intersection of venture backing and European innovation programs, which is shaping its financial runway as it advances antibiotic candidates into clinical testing.
The drug targets Gram-negative pathogens, including Acinetobacter baumannii strains resistant to last-line antibiotics such as carbapenems and colistin.
Funding will also go toward regulatory work, scaling manufacturing, and pipeline expansion. With antibiotic resistance driving an urgent global health threat, Omnix sees itself positioned to deliver solutions where traditional drugs fail.
Harel Insurance’s VP and tech investment head Tomer Goldberg said supporting biotech innovation is critical: “The rise of antibiotic-resistant infections is not just a medical crisis, it is a societal one”.
Companies like Omnix are essential to ensuring the development of effective treatments that protect lives and promote long-term wellbeing.
CEO Dr. Moshik Cohen-Kutner called the raise a turning point: “With co-leadership from Harel and the EIC Fund, and continued shareholder trust, we can now finish OMN6’s Phase II studies, strengthen regulatory and manufacturing capacity, and push our pipeline forward.”
CSO Dr. Niv Bachnoff described OMN6’s unique action profile: rapid pore-forming activity, high selectivity for bacterial membranes, and engineered stability. These features reduce the chance of resistance emerging while enabling fast, effective treatment.
We are now in a position to show OMN6’s potential to transform treatment of multidrug-resistant infections
CSO Dr. Niv Bachnoff
With the Series C closed, Omnix moves into a decisive stage of development. If Phase II results deliver, the company could become a key player in reshaping how the world fights antibiotic-resistant bacteria.
